Literature DB >> 25617291

Re: Joint meeting for Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management Advisory Committee (DSARM AC), September 17, 2014.

Allen D Seftel.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25617291     DOI： 10.1016/j.juro.2014.11.060

Source DB:  PubMed          Journal:  J Urol        ISSN： 0022-5347            Impact factor:   7.450


× No keyword cloud information.
  10 in total

Review 1.  The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder.

Authors:  Sheryl A Kingsberg; Anita H Clayton; James G Pfaus
Journal:  CNS Drugs       Date:  2015-11       Impact factor: 5.749

2.  Association Between Direct-to-Consumer Advertising and Testosterone Testing and Initiation in the United States, 2009-2013.

Authors:  J Bradley Layton; Yoonsang Kim; G Caleb Alexander; Sherry L Emery
Journal:  JAMA       Date:  2017-03-21       Impact factor: 56.272

3.  Maximizing the Post-Approval Safety of Flibanserin: A Role for Regulators, Clinicians, and Patients.

Authors:  Sheriza N Baksh; Walid F Gellad; G Caleb Alexander
Journal:  Drug Saf       Date:  2016-05       Impact factor: 5.606

Review 4.  Sexual Function Across Aging.

Authors:  Anita H Clayton; Veronica Harsh
Journal:  Curr Psychiatry Rep       Date:  2016-03       Impact factor: 5.285

Review 5.  Alternatives to testosterone replacement: testosterone restoration.

Authors:  Andrew McCullough
Journal:  Asian J Androl       Date:  2015 Mar-Apr       Impact factor: 3.285

Review 6.  Flibanserin for Treating Hypoactive Sexual Desire Disorder.

Authors:  Jae Hong Sang; Tae-Hee Kim; Soo Ah Kim
Journal:  J Menopausal Med       Date:  2016-04-26

7.  Bulbocavernosus muscle area as a novel marker for hypogonadism.

Authors:  Nikhil Gupta; Maria Carvajal; Michael Jurewicz; Bruce R Gilbert
Journal:  Asian J Urol       Date:  2016-11-28

8.  Testosterone and "Age-Related Hypogonadism"--FDA Concerns.

Authors:  Christine P Nguyen; Mark S Hirsch; David Moeny; Suresh Kaul; Mohamed Mohamoud; Hylton V Joffe
Journal:  N Engl J Med       Date:  2015-08-20       Impact factor: 91.245

Review 9.  A summary of the controversy surrounding off-label medications in men's health.

Authors:  Adam Parker; Matthew Bruha; Oluwaseun Akinola; Charles Welliver
Journal:  Transl Androl Urol       Date:  2016-04

Review 10.  Testosterone therapy in the new era of Food and Drug Administration oversight.

Authors:  Bethany Desroches; Taylor P Kohn; Charles Welliver; Alexander W Pastuszak
Journal:  Transl Androl Urol       Date:  2016-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.